Corbus Pharmaceuticals Holdings, Inc. CRBP
Nov 4, 2026, 3:28 PM EST
- YTD
- -54.98%
- 1 year
- -67.42%
- Market cap
- 70.89M
- EPS (ttm)
- -6.11
- Shares out
- 12.18M
- Forward P/E
- -2.51
- YTD return
- -54.98%
- 1-year return
- -67.42%
- Volume
- 1.63M
- Avg volume
- 1.00M
- Open
- 3.97
- Previous close
- 3.87
- Day's range
- 3.61 – 4.10
- 52-week range
- 3.67 – 12.15
- Beta
- 2.56
- Analysts
- Strong Buy
- Price target
- 56.78 (+1449.2%)
6M -6.98 (-65.42%)
Key statistics
- Enterprise value
- 2.58M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -25.40M
- Total cash
- 159.36M
- Total debt
- 3.61M
- Return on equity
- -51.32%
- Short % of float
- 24.72%
- 50-day average
- 16.87
- 200-day average
- 37.65
Analyst view
Consensus: strong buy
- Target (low)
- 35.00
- Target (mean)
- 56.78
- Target (high)
- 75.00
- Strong buy3
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.26.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.99 | -1.15 | -0.16 | -16.16% |
| Aug 6, 2024 | Jun 1, 2024 | -1.16 | -0.90 | +0.26 | +22.41% |
| May 7, 2024 | Mar 1, 2024 | -1.09 | -0.83 | +0.26 | +23.85% |
| Mar 12, 2024 | Dec 1, 2023 | -2.36 | -1.81 | +0.55 | +23.31% |
| Nov 7, 2023 | Sep 1, 2023 | -2.06 | -2.27 | -0.21 | -10.19% |
| Aug 8, 2023 | Jun 1, 2023 | -3.10 | -2.05 | +1.05 | +33.87% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2, 2024 | Piper Sandler | init | — | Overweight |
| Aug 7, 2024 | RBC Capital | reit | Outperform | Outperform |
| Aug 7, 2024 | Oppenheimer | main | Outperform | Outperform |
| Aug 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 10, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Jun 26, 2024 | B. Riley Securities | init | — | Buy |
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- corbuspharma.com
News
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Now Rated “Moderate Buy” by Wall Street Analysts 
Corbus Pharmaceuticals To Present Late Breaking Data From CRB-913 Canyon-1 Phase 1B Study At Obesity Week 2026 
Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026 
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer 
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data? 
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study 
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target 
Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects' 
Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects' 
12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on CRBP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTMEYER ANNE | Director | Stock Award(Grant) | May 29, 2024 | 2,783 |
| CATLIN AVERY W | Director | Stock Award(Grant) | May 29, 2024 | 4,350 |
| COHEN YUVAL | Chief Executive Officer | Sale | Jun 17, 2024 | 77,221 |
| CORMORANT ASSET MANAGEMENT ,L.P | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 19, 2024 | 0 |
| HOLMER ALAN F | Director | Conversion of Exercise of derivative security | Jun 13, 2024 | 5,829 |
| JACQUES RACHELLE SUZANNE | Director | Stock Award(Grant) | May 29, 2024 | 2,783 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cormorant Asset Management, LP | 19.50% | 2,375,000 | 31.25M | Sep 29, 2024 |
| Octagon Capital Advisors LP | 9.15% | 1,115,000 | 14.67M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 7.49% | 912,552 | 12.01M | Sep 29, 2024 |
| Blackrock Inc. | 6.59% | 802,721 | 10.56M | Sep 29, 2024 |
| Vanguard Group Inc | 5.30% | 645,650 | 8.50M | Sep 29, 2024 |
| Tang Capital Management, LLC | 4.93% | 600,000 | 7.90M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 3.21% | 391,276 | 5.15M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.70% | 329,220 | 4.33M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.21% | 269,243 | 3.54M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.39% | 169,055 | 2.22M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.85% | 104,055 | 1.37M | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 0.56% | 68,254 | 898.22K | Oct 30, 2024 |